Page 13 - Flipbook

Stage- wise Drug and Therapy Development in Prostate Cancer
Agents moved upfront- fine tuning
Clarity on sequencing
Targeted Therapy

Newly diagnosed

mHSPC

Primary
Unmet Needs progressive
mHSPC
Localised or locally Biochemical Terminal
advanced prostate mCRPC disease
cancer recurrence (death)

nmCRPC

Hong JH, Kim IY. Korean J Urol. 2014;55:153-60.
mCRPC, metastatic castration-resistant prostate cancer; Mottet N, et al. EAU/ESTRO/ESUR/SIOG Guidelines on Prostate Cancer 2017.
mHSPC, metastatic hormone-sensitive prostate cancer; Available from: http://uroweb.org/guideline/prostate-cancer. Accessed February 2018.
nmCRPC, non-metastatic castration-resistant prostate cancer.
Adapted from: Scher HI, et al. J Clin Oncol. 2016;34:1402-18.